Recombinant Human Methionine Synthase (MTR) Protein (His-SUMO)

Beta LifeScience SKU/CAT #: BLC-10347P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Methionine Synthase (MTR) Protein (His-SUMO)

Beta LifeScience SKU/CAT #: BLC-10347P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description Recombinant Human Methionine Synthase (MTR) Protein (His-SUMO) is produced by our E.coli expression system. This is a protein fragment.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb Q99707
Target Symbol MTR
Synonyms MTRMethionine synthase; EC 2.1.1.13; 5-methyltetrahydrofolate--homocysteine methyltransferase; Vitamin-B12 dependent methionine synthase; MS
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His-SUMO
Target Protein Sequence SLKERRYLPLSQARKSGFQMDWLSEPHPVKPTFIGTQVFEDYDLQKLVDYIDWKPFFDVWQLRGKYPNRGFPKIFNDKTVGGEARKVYDDAHNMLNTLISQKKLRARGVVGFWPAQSIQDDIHLYAEAAVPQAAEPIATFYGLRQQAEKDSASTEPYYCLSDFIAPLHSGIRDYLGLFAVACFGVEELSKAYEDDGDDYSSIMVKALGDRLAEAFAEELHERVRRELWAYCGSEQLDVADLRRLRYKGIRPAPGYPSQPDHTEKLTMWRLADIEQSTGIRLTESLAMAPASAVSGLYFSNLKSKYFAVGKISKDQVEDYALRKNISVAEVEKWLGPILGYDTD
Expression Range 923-1265aa
Protein Length Partial
Mol. Weight 55.0kDa
Research Area Epigenetics And Nuclear Signaling
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Catalyzes the transfer of a methyl group from methylcob(III)alamin (MeCbl) to homocysteine, yielding enzyme-bound cob(I)alamin and methionine in the cytosol. MeCbl is an active form of cobalamin (vitamin B12) used as a cofactor for methionine biosynthesis. Cob(I)alamin form is regenerated to MeCbl by a transfer of a methyl group from 5-methyltetrahydrofolate. The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMADHC, MTRR (methionine synthase reductase) and MTR which may contribute to shuttle safely and efficiently cobalamin towards MTR in order to produce methionine.
Subcellular Location Cytoplasm.
Protein Families Vitamin-B12 dependent methionine synthase family
Database References
Associated Diseases Homocystinuria-megaloblastic anemia, cblG complementation type (HMAG); Neural tube defects, folate-sensitive (NTDFS)
Tissue Specificity Widely expressed. Expressed at the highest levels in pancreas, heart, brain, skeletal muscle and placenta. Expressed at lower levels in lung, liver and kidney.

Gene Functions References

  1. 12 articles were included in this study. The pooled results did not reveal a significant association of the MTR A2756G polymorphism with Nonsyndromic Cleft Lip With or Without Cleft Palate risk (G vs. A: OR = 0.95, 95% CI = 0.82-1.11, p = 0.55). PMID: 30004262
  2. GG homozygous and G alleles of methionine synthase A2756G polymorphism were not associated with risks of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), the subtype of NHL including the diffuse large B-cell lymphoma and follicular lymphoma. PMID: 28742198
  3. Data indicate that two noncoding 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) variants, rs28372871 and rs1131450 were independently associated with a significantly increased risk of prostate cancer (PCa). PMID: 27808252
  4. no difference in genotype frequencies between pre-eclampsia patients and controls PMID: 27806663
  5. Based on the results, an MTRA2756G polymorphism which changes activity and stability of the methionine synthase associated with prostate cancer in men. PMID: 28724269
  6. MTR CpG sites were hypermethylated in preterm placenta. Methylated CpG sites were negatively associated with maternal plasma vitamin B12 levels. PMID: 28617183
  7. MS A2756G polymorphism may not be a risk factor for hematological cancer. PMID: 29310321
  8. MTHFR A1298C and MS A2756G polymorphisms may be unrelated to male infertility. PMID: 28081209
  9. People with late-life depression carrying MTR2756 AA genotype have higher risk of cognitive impairment than those carrying G allele. PMID: 27111719
  10. Data suggest that the MTR-A2756G polymorphism is associated with male infertility risk. PMID: 26905524
  11. MTR A2756G single nucleotide polymorphism is significantly associated with gastric cancer risk in Korea. PMID: 26833750
  12. There was a significant positive correlation between serum concentrations of vitamin B12 and regional GM (grey matter ) volume in APOE epsilon4 carriers with AD but not in non-carriers. PMID: 25919635
  13. According to our results, the MTR A2756G polymorphism was associated with the risk of retinoblastoma in Iranian patients. PMID: 26595280
  14. MTR genetic polymorphisms are risk factor for predicting cardiovascular manifestations in Marfan syndrome. PMID: 26063524
  15. no association of rs1805087 with non-obstructive azoospermia PMID: 26196053
  16. Data suggest impaired folate metabolism down-regulates placenta trophoblast proliferation, viability, invasive capacity, and progesterone secretion; silencing MTR gene down-regulates cell proliferation and up-regulates progesterone secretion. PMID: 26299783
  17. Studies do not indicate a major role of the 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) rs1805087 A> G polymorphism in modulating non-Hodgkin lymphoma (NHL) risk. PMID: 24956146
  18. An increase of placental mRNA levels in the pre-eclampsia group was observed for MTR and cystathionine gamma-lyase. PMID: 25801727
  19. Methionine synthase (MTR) and methionine synthase reductase (MTRR) polymorphisms were significantly associated with the increased neural tube defects risk in a Chinese population. PMID: 26334892
  20. In summary, hyperhomocysteinemia was related with increased risk of decline in executive functioning, complex attention, cognitive flexibility, and memory in postmenopausal women. PMID: 25822709
  21. Results show that an association of the G-allele of the methionine synthase variant c.2756A>G (D919G) with global DNA methylation. PMID: 25531253
  22. Our results show that elevated homocysteine plasma level may characterize schizophrenia patients' male siblings. PMID: 24051177
  23. results suggest that methionine synthase in the villous trophoblast participates in the metabolism of homocysteine by using folate PMID: 25277375
  24. our study provides evidence suggesting that MTR A2756G is associated with a reduced risk of developing childhood ALL. PMID: 23906019
  25. 5-methyltetrahydrofolate-homocysteine methyltransferase gene polymorphism does not have modification effects on the risk of CRC. PMID: 25077679
  26. Genetic association replicative and exploratory studies identify SNPs in ADA and MTR highly associated with isolated Neural tube defects (NTD)and SNP in ARID1A and ALDH1A2 associated with NTDs in whites and African Americans respectively. PMID: 25293959
  27. Our findings suggest a causal role for maternal homocysteine (1-C metabolism) in fetal growth PMID: 25052622
  28. This meta-analysis demonstrated a suggestive result that the A66G variant in MTRR, but not the A2756G in MTR, may be associated with the increase of congenital heart disease risks. PMID: 24595101
  29. found limited evidence that the maternal MTR rs1804742 appeared to interact with higher folic acid levels to influence childhood acute lymphoblastic leukemia risk PMID: 24087922
  30. Results show that regulatory variants of the MTR gene increase CHD risk by reducing MTR expression and inducing the homocysteine accumulation and elevation. PMID: 23798577
  31. Trend analyses also revealed the marginally significant lower risk of chronic kidney disease with increasing number of MTR A2756G G allele. PMID: 23595572
  32. Present data do not support a role for MTR 2756A>G as independent maternal risk factor for a Down syndrome birth. PMID: 24150725
  33. data suggest that the interaction of methionine synthase with MMACHC may play a role in the regulation of the cellular processing of cobalamins that is required for cobalamin cofactor synthesis PMID: 23825108
  34. No association between MS A2756G polymorphism and cervical cancer was detected in the worldwide population. PMID: 23864153
  35. [meta-analysis] MTR A2756G polymorphisms are not associated with risks for neural tube defects in Caucasian children. PMID: 23425389
  36. There was a significant association of breast cancer risk with MTR 2756 GG and AA polymorphism. PMID: 24166605
  37. A review of the influences of genetic polymorphisms in methionine synthase on the occurrence of adverse effects from methotrexate therapy. PMID: 23986219
  38. MTR 2756 AA genotypes were associated with higher Hcy concentrations (16.6 and 10.1 mumol/L; p<0.05) compared to subjects harboring the MTHFR 677 CT/CC and the MTR 2756 AG genotypes (10.5, 9.7 and 9.5 mumol/L, respectively). PMID: 23954866
  39. MTR SNPs do not appear to play a major role in lymphoma susceptibility in a Spanish population. PMID: 23818366
  40. This meta-analysis suggests that there is no significant association between the MTR A2756G polymorphism and digestive system cancer risk. PMID: 23613867
  41. findings suggest that MTR A2756G polymorphism is not associated with altered susceptibility to breast cancer, while the observed decreased risk in Caucasians PMID: 23845785
  42. MTR A2756G polymorphism is not associated with CRC/CRA susceptibility and that gene-environment interaction may exist. PMID: 23593229
  43. Methionine synthase 2756AA genotype and 2756A-TS 6-bp allele combination are predisposing factors for recurrent pregnancy loss in a sample of South Korean women. PMID: 23415967
  44. no associations between the MTR A2756G polymorphism and neural tube defects risk were found in meta-analysis of genetic models PMID: 23438943
  45. no significant association was found between TYMS or the MTR polymorphisms and the risk of primary liver cancer PMID: 21956592
  46. meta-analysis indicated that MTRR A66G polymorphism, but not MTR A2756G, is significantly associated with maternal risk for neural tube defects in Caucasians PMID: 23266814
  47. These findings indicate that locus A2756G in the MTR gene may play a role in susceptibility to congenital anomalies of the cardiovascular system in West Siberia. PMID: 22855024
  48. an increase in the risk of colorectal adenomas associated with methionine synthase 2756GG genotype PMID: 22407825
  49. No statistically significant association with prostate cancer was detected for the polymorphic locus A2756G of methionine synthase gene. PMID: 22803112
  50. We found weak evidence of a recessive effect of the G allele in MTR A2756G (odds ratio, 1.61 [95% confidence interval, 0.98-2.66]; p=0.06)and risk for coronaryh artery diseae. PMID: 22339686

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

More from High-Quality Recombinant Proteins
Sale
Recombinant Human PARP2 Protein (N-GST & C-6xHis)
  • Molecule: PARP2;
  • Species: Human;
  • Expression system: Baculovirus;
  • Tag: N-terminal GST-tagged and C-terminal 6xHis-tagged;
  • Sequence: Full Length;
CAT#: BLC-11423P

Save $650
Sale
Greater than 85% as determined by SDS-PAGE.
Recombinant Human ACP3 Protein (C-10xHis)
  • Molecule: ACP3;
  • Species: Human;
  • Expression system: Baculovirus;
  • Tag: C-terminal 10xHis-tagged;
  • Sequence: Partial of Isoform 2;
CAT#: BLC-11438P

Save $650
Sale
Greater than 90% as determined by SDS-PAGE.
Recombinant Human MUSK Protein (TBD)
  • Molecule: MUSK;
  • Species: Human;
  • Expression system: in vitro E.coli expression system;
  • Tag: TBD;
  • Sequence: Partial;
CAT#: BLC-11435P

Save $650
Sale
Greater than 90% as determined by SDS-PAGE.
Recombinant Human SLC39A1 Protein (N-GST)
  • Molecule: SLC39A1;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: N-terminal GST-tagged;
  • Sequence: Cytoplasmic Domain;
CAT#: BLC-11425P

Save $650
Sale
Greater than 90% as determined by SDS-PAGE.
Recombinant Human TLR5 Protein (C-6xHis)
  • Molecule: TLR5;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: C-terminal 6xHis-tagged;
  • Sequence: Partial;
CAT#: BLC-11405P

Save $650
Sale
Greater than 85% as determined by SDS-PAGE.
Recombinant Human GPR20 Protein (N-10xHis)
  • Molecule: GPR20;
  • Species: Human;
  • Expression system: in vitro E.coli expression system;
  • Tag: N-terminal 10xHis-tagged;
  • Sequence: Full Length;
CAT#: BLC-11447P

Save $650
Recently viewed